IP Library Granted Patent US 11,471,426
Granted Patent B2
US 11,471,426 · App. 16/829,868 · Granted Oct 18, 2022

Compositions comprising quinone and/or quinol and methods of preparations and use thereof

Inventor: Barrie Tan (Hadley, MA)
Assignee: American River Nutrition, LLC
A61K31/12A61K9/0053A61K31/09
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,471,426
App. No.
16/829,868
Granted
Oct 18, 2022
Kind
B2
Abstract

The present embodiments are directed to compositions of quinones and/or quinols, such as, but not limited to, ubiquinone and/or ubiquinol, vitamin E quinone and/or vitamin E quinol, vitamin K quinone and/or vitamin K quinol, menaquinones and/or menaquinols, and pyrroloquinoline quinone and/or pyrroloquinoline quinol, and methods for preparations and use thereof. The present embodiments are also directed to compositions of reduced forms of curcuminoid and methods for preparations and use thereof.

Claims (64)

1. A method of preparing a composition comprising Compound C, comprising:

contacting Compound A having the formula of

optionally in a solvent, wherein the solvent is free of ethanol,

with Compound B having the formula of

to form Compound C having the formula of

wherein:

R 5 is H, OH, NH 2 , NO 2 , R 6 —C(O)—, optionally substituted carbocycle, optionally substituted aryl group, optionally substituted heteroaryl group, branched or unbranched alkyl alcohol, halo, branched or unbranched alkyl, branched or unbranched alkenyl, branched or unbranched alkenyl ester, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, or alkylsulfanyl; and

R 1 , R 2 , R 3 , R 4 , R 6 , and R 8 are each, independently, H, OH, NH 2 , NO 2 , optionally substituted carbocycle, optionally substituted aryl group, optionally substituted heteroaryl group, branched or unbranched alkyl alcohol, halo, branched or unbranched alkyl, branched or unbranched alkenyl branched or unbranched carboxylic acid, branched or unbranched alkyl ester, branched or unbranched alkenyl ester, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, or alkylsulfanyl; or R 2 and R 3 are together optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and

wherein the Compound A has the formula of

and wherein n, o, p, q, or r independently is 1-20.

2. The method of claim 1 , wherein Compound B has the formula of

3. The method of claim 1 , wherein the solvent is a non-toxic terpenoid having the formula of

Formula V and m is 0-10.

4. The method of claim 3 , wherein the non-toxic terpenoid has the formula of

5. The method of claim 1 , wherein the method comprises:

contacting Compound A having the formula of

in the solvent having the formula of

with Compound B having the formula of

to form Compound C having the formula of

wherein m is 0-10.

6. The method of claim 5 , wherein the method comprises:

contacting Compound A having the formula of

in the solvent having the formula of

with Compound B having the formula of

to form the compound having the formula of

7. The method of claim 1 , wherein the method comprises:

a. heating the solvent in a mixing vessel to about 35-75° C.;

b. adding Compound A to the solvent of the step a to form a translucent solution;

c. adding Compound B to the solution of step b to form a mixture and stirring the mixture;

d. replacing the air in the vessel with an inert gas and sealing the vessel air tight; and

e. stirring the mixture of step d for a period of time at an elevated temperature.

8. The method of claim 7 , wherein the inert gas is Nitrogen or Argon.

9. The method of claim 7 , wherein the elevated temperature is in a range of about 30-100° C., about 40-80° C. or about 50-70° C.

10. The method of claim 7 , wherein the period of time is about 1 to about 13 days, about 2 to about 10 days, or about 3 to about 6 days.

11. The method of claim 7 , wherein the starting weight ratio of Compound A:Compound B; the solvent is in a range of about 4:0.5:4 to about 4:4:4.

12. The method of claim 7 , wherein the starting weight ratio of Compound A:Compound B; the solvent is about 4:2:4.

13. A composition prepared according to the method of claim 1 , the composition comprising:

Compound A having the formula of

Compound B having the formula of

Compound C having the formula of

Compound D having the formula of

and

optionally a solvent with the proviso that the non-toxic solvent is not ethanol,

wherein:

R 5 is H, OH, NH 2 , NO 2 , R 6 —C(═O)—, optionally substituted carbocycle, optionally substituted aryl group, optionally substituted heteroaryl group, branched or unbranched alkyl alcohol, halo, branched or unbranched alkyl, branched or unbranched alkenyl, branched or unbranched alkenyl ester, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, or alkylsulfanyl; and

R 1 , R 2 , R 3 , R 4 , R 6 , and R 8 are each, independently, H, OH, NH 2 , NO 2 , optionally substituted carbocycle, optionally substituted aryl group, optionally substituted heteroaryl group, branched or unbranched alkyl alcohol, halo, branched or unbranched alkyl, branched or unbranched alkenyl, branched or unbranched carboxylic acid, branched or unbranched alkyl ester, branched or unbranched alkenyl ester, amide, cyano, alkoxy, haloalkyl, aklylsulfonyl, nitrite, or alkylsulfanyl; or R 2 and R 3 are together optionally substituted cycloalkyl, optionally substituted cycloheteroalkyl, optionally substituted aryl, or optionally substituted heteroaryl; and

wherein the Compound A has the formula of

and wherein n, o, p, q, or r independently is 1-20.

14. The composition of claim 13 , wherein the solvent is the non-toxic terpenoid having the formula of

wherein m is 0-10.

15. The composition of claim 14 , wherein the non-toxic terpenoid has the formula of

16. The composition of claim 13 , wherein the weight ratio of the total amount of Compound A and Compound C:Compound B is in a range of about 5:1 to about 1:5, about 3:1 to about 1:3, or about 2:1 to about 1:2.

17. The composition of claim 13 , wherein the weight ratio of Compound A:Compound C is in a range of about 99.9:0.1 to about 0.1:99.9, 40:60 to about 1:99, about 20:80 to about 1:99, about 15:85 to about 7:93, about 13:87 to about 7:93, about 13:87 to about 8:92, or about 13:87 to about 8:91.

18. The composition of claim 13 , wherein the composition is formulated in a form suitable for oral consumption or oral administration and the form is selected from the group consisting of a softgel, a capsule, 2-piece liquid-filled capsule, a bar, confectionary, chocolate, a powder, an oral suspension, a tablet, a pill, a hard-shell, a truffle, a ganache, a truffle ganache, a gum, and a chewable form.

19. A method, the method comprising:

mitigating or treating statin-induced CoQ10 diseases in a subject comprising administering to the subject the composition of claim 13 ;

improving cardiac functions, increasing energy, increasing bone mineralization, prevention of joint osteophyte growth prevention and reversion of gall and kidney stones, reversal of arterial calcification, preventing statin-induced myopathy, preventing blood-thinning med-induced dementia, increasing myogenesis, preventing sarcopenia, preventing cancer-induced cachexia, increasing zest and thrive, preventing fibromyalgia, decreasing fatigue, preventing energy deficits, or improving general metabolic synthesis of proteins, CoQ10, or Vitamin K2 in a subject comprising administering to the subject the composition of claim 13 ;

increasing bioavailability and bioaccessibility of a second composition in a subject comprising administering to the subject the composition of claim 13 with the second composition;

increasing absorption into an endothelial or internal surface skin of a dermatological composition, comprising administering to a subject the composition of claim 13 with the dermatological composition;

improving mitochondrial function or increasing mitochondrial reproduction in a subject comprising administering to a subject the composition of claim 13 ;

improving neurological regeneration in a subject comprising administering to the subject the composition of claim 13 ; or

mitigating or treating nonalcoholic fatty liver in a subject comprising administering to a subject the composition of claim 13 ;

wherein the subject of any of the foregoing can optionally be a subject in need thereof.

20. The method of claim 7 , wherein the temperature of step a, is about 45-65° C.

Assignments (3)
SECURITY INTEREST Recorded Oct 20, 2025
From: DESIGNS FOR HEALTH, INC.
To: TCW PT MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 072608/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2025
From: AMERICAN RIVER NUTRITION, LLC
To: DESIGNS FOR HEALTH, INC.
Reel/Frame 071596/0243 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2020
From: TAN, BARRIE
To: AMERICAN RIVER NUTRITION, LLC
Reel/Frame 053563/0212 →
Continuity (2)
Provisional Application 62915649 · Oct 16, 2019
Related Publication 20210113491A1 · Apr 22, 2021
Cited By (1)
US 12,226,374